12 research outputs found
CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment
RETRACTED ​ARTICLE: Isolation, purification and partial characterization of a lectin protein from the seeds of green seeded chickpea PUSA hara chana (Cicer arietinum L.)
Ipomoelin, a Jacalin-Related Lectin with a Compact Tetrameric Association and Versatile Carbohydrate Binding Properties Regulated by Its N Terminus
Hippophae rhamnoides N-glycoproteome analysis: a small step towards sea buckthorn proteome mining
Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment
Myeloid-derived suppressor cells in B cell malignancies
Tumor cells use several mechanisms such as soluble immune modulators or suppressive immune cells to evade from anti-tumor responses. Immunomodulatory cytokines, such as transforming growth factor-beta, interleukin (IL)-10, and IL-35, soluble factors, such as adenosine, immunosuppressive cells, such as regulatory T cells, NKT cells and myeloid-derived suppressor cells (MDSCs), are the main orchestra leaders involved in immune suppression in cancer by which tumor cells can freely expand without immune cell-mediated interference. Among them, MDSCs have attracted much attention as they represent a heterogenous population derived from myeloid progenitors that are expanded in tumor condition and can also shift toward other myeloid cells, such as macrophages and dendritic cells, after tumor clearing. MDSCs exert their immunosuppressive effects through various immune and non-immune mechanisms which make them as potent tumor-promoting cells. Although, there are several studies regarding the immunobiology of MDSCs in different solid tumors, little is known about the precise characteristics of these cells in hematological malignancies, particularly B cell malignancies. In this review, we tried to clarify the precise role of MDSCs in B cell-derived malignancies